© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
June 02, 2022
Drs Tom Powles and Brian Shimkus muse on the unmet needs of kidney cancers and treatments on the horizon to look forward to.
A discussion on how patient risk groups play into deciding on the appropriate treatment for renal cell carcinoma.
May 26, 2022
Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.
Dr Brian Shimkus describes how he doses lenvatinib for renal cell carcinoma treatment.
May 19, 2022
A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.
May 02, 2022
Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.
A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.
Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.
April 21, 2022
A look at the current unmet needs in front-line renal cell carcinoma treatment.
Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.